Co-treatment with KPA also decreased the expression of genes (Figure 7I,J), regulating the progression of fibrosis (e.g., COL6A3, AEBP1, SPARC, TNC, LAMB1, BGN) and hepatocellular carcinoma (e.g., COL4A1, COL4A2, TUFT1, VCAN, NID1). Here, TUFT1 is linked to hepatocellular carcinoma.